Related Experiment Video
Updated: Jun 26, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.
Frontiers in Immunology
|June 25, 2026
Summary
SSGJ-608 effectively treats moderate-to-severe plaque psoriasis in Chinese patients. Both 80mg every two weeks and 160mg every four weeks dosing regimens showed comparable efficacy and favorable safety profiles.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- SSGJ-608 is an anti-interleukin-17A monoclonal antibody.
- It has demonstrated promising efficacy in preliminary trials for moderate-to-severe psoriasis.
Purpose of the Study:
- To evaluate SSGJ-608 at two different dosing intervals (80mg Q2W and 160mg Q4W).
- To assess efficacy and safety in patients with moderate-to-severe plaque psoriasis.
Main Methods:
- A phase 3, multicenter, randomized, open-label trial.
- 770 patients received SSGJ-608 (80mg Q2W or 160mg Q4W) for 12 weeks.
- Co-primary endpoints included PASI75 and sPGA 0/1 response rates at week 12.
Main Results:
- Both dosing regimens achieved comparable PASI75 (92.7% vs. 95.1%) and sPGA 0/1 (80.3% vs. 79.0%) response rates at week 12.
- High response rates were observed in patients previously treated with anti-IL-17 therapy.
- Common adverse events included hypertriglyceridemia and upper respiratory tract infections; a favorable safety profile was noted.
Conclusions:
- SSGJ-608 is highly effective for moderate-to-severe plaque psoriasis in Chinese patients.
- Both 80mg Q2W and 160mg Q4W regimens are effective and well-tolerated.
- The drug shows particular promise for patients previously treated with anti-IL-17 therapies.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...